The goals of this study were, first, to determine whether BSN exerts the anti-cancer effects through the abrogation of the STAT3 signaling pathway in NSCLC cells; second, to analyze whether BSN can enhance the antitumor effects of paclitaxel, chemotherapeutic drug used extensively to treat NSCLC patients; third, to investigate whether BSN potentiates the effects of these targeted therapies in vivo. This evidence concerns the gene BSN and non-small cell lung carcinoma.